Gilead Sciences, Inc. (NASDAQ: GILD), a research-based biopharmaceutical company, is focused on discovering, developing, and commercializing novel medicines to address unmet medical needs. The company’s aim is to improve the care of patients suffering from life-threatening diseases with every new discovery and experimental drug candidate. Primary areas of focus include: antivirals, cardiovascular conditions and respiratory diseases. For further information, visit the Company’s web site at www.gilead.com.
- 18 years ago
QualityStocks
Gilead Sciences, Inc. (NASDAQ: GILD)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory…
-
Wrap Technologies Inc. (NASDAQ: WRAP) Positions Non-Lethal Innovation at the Center of Public Safety Reform
WRAP offerings illustrate a broader industry trend toward building connected ecosystems rather than standalone products.…
-
Brownfield Gold Projects Could Hold an Edge in Today’s Permitting Environment
Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.…